Perception is everything — especially when it comes to the value of software startups and total addressable markets (TAM). During 2020 and 2021, as COVID bit into the economy, tech products turned o
Hello and welcome back to our regular morning look at private companies, public markets and the gray space in between. Today we’re digging into SoftBank’s latest earnings slides. Not only
“What Karius is good at is identifying those novel microbes before they become an outbreak like coronavirus,” says Mickey Kertesz, a chief executive whose life sciences startup just hauled
Despite near-miraculous advances in the treatment of cancer in the U.S. and around the world, the disease remains the second leading cause of death in America. The problem is that every manifestation
Pear, a six-year-old, Palo Alto, Calif.-based seed-stage firm whose bets on nascent startups are closely watched by early-stage investors, has closed on $160 million in capital commitments from a wide
Pear, a Palo Alto-based seed-stage fund that has made its name through early bets on Guardant Health, DoorDash, Memebox and Gusto, hosted its sixth annual demo day this week in what proved to be a sco
This morning, a publicly traded transplant diagnostics company called CareDx, along with Stanford University, sued another publicly traded genetic testing company, Natera, for patent infringement. Muc
Guardant Health, a four-year-old, Redwood City, Ca.-based biotech company that sells blood tests to track and potentially detect cancer, has raised a whopping $360 million from investors, bringing its
Guardant Health, a three-year-old, Redwood Shores, Ca.-based company whose non-invasive genomic sequencing test for cancer requires just two vials of blood, has raised nearly $100 million in Series D
Guardant Health announced today that it has raised $50 million in Series C funding for its biopsy-free blood cancer screening test Guardant360. This puts the total funding for the medical technology s
When testing for the possibility of certain types of cancer, doctors often do surgery to retrieve biopsies for genetic analysis. But when a patient has already had cancer, and is testing for a possibi